I’m excited to share that my PhD thesis work (helped along by many talented colleagues/collaborators) is now published! It’s a great read & reveals a new paradigm for combating antibiotic resistance
#antibioticresistance#effluxpumps#MRSA#therapeutics
https://t.co/VtFflvIeH1
An engaging discussion at last night’s Biomed Entrepreneurship class!
We were grateful to have Michal Gilon-Yanai from Two Lanterns Venture Partners & Joseph Ferino from @BrownRudnickLLP who shared their knowledge/ perspectives on startup teams & the legal essentials of startups
📢 Check out this innovative & game-changing biotechnology from NYU for generating a durable immune response against drug-resistant cancer cells! ⬇️
A new study from @nyulangone’s @DrBenNeel & Dr. Shohei Koide describes a revolutionary biotechnology for treating drug-resistant cancer cells.
TOV is proud to help facilitate the commercialization of this game-changing innovation.
Learn more - https://t.co/hg3ULVRErk
📢Norovirus Link to Crohn’s Disease May Point to New Therapies. https://t.co/KGsPrDX323
TOV is excited to help facilitate the commercialization of this innovative, early-stage therapeutic for the treatment of #CrohnsDisease from the @cadwellLab and Dr. Shohei Koide’s group.
New research from @NYUDental has found a topical gel treatment for gum disease. “No current treatment for gum disease simultaneously reduces inflammation, limits disruption to the oral microbiome, and prevents bone loss." https://t.co/pDcj49mTqv
.@nyulangone's @KathrynMooreLab developed a novel approach to suppress proinflammatory signals for the treatment of chronic inflammatory diseases! They ID'd the immune-augmenting role of the long noncoding RNA CHROMR and developed antisense oligonucleotides to block its function.
The TOV team is at the #RESI conference in #Boston showcasing @nyuniversity's exciting portfolio of technologies and startups to #lifescience investors! If you are attending and would like to connect, please reach out.
Great turnout for the first class in our fall course: Introduction to Biomedical Entrepreneurship - Foundations of Biomedical Startups!
https://t.co/FIr0hhYNIz
Llamas to the rescue🦙! Check out this exciting nanobody technology for combatting #coronavirus infections from @NYUAbuDhabi that @NYUTOV is looking to partner with industry for commercialization!
Researchers at @NYUAbuDhabi have developed a potential antiviral strategy against #COVID19. They identified miniaturized antibodies (#nanobodies) that selectively bind & stabilize Nsp9, an essential protein for viral replication, in a way that renders the protein non-functional.
Just announced! @nyulangone startup Canaery secured over $4M in seed funding to speed up development of its scent sensing platform. Langone Health participated in the funding round as an investor, making Canaery the 3rd investment from our new venture fund
https://t.co/yJqQH519L7
What if you could apply sunscreen once in the morning and remain protected from the sun the entire day?@nyuniversity Chemistry Professor Marcus Weck and his lab are working to make that a reality.
https://t.co/mvbgfy637k
📢@nyulangone innovators - A reminder that Therapeutics Alliances, NYU Langone's internal drug development accelerator, is currently seeking proposals for target discovery, target validation, and assay development projects.
Application deadline is June 27
https://t.co/i6Kkm0cHZx
The Trabolsi Lab at @NYUAbuDhabi has developed novel organic #nanoparticles for oral #insulin delivery that could revolutionize #diabetes care! These nanoparticles can release insulin in a glucose-responsive manner to lower blood sugar levels. https://t.co/PvXSXUMJ5z
A research team led by Dr. Ann Marie Schmidt at @NYULangone developed a new way to treat #diabetes-associated diseases w/ a #SmallMolecule inhibitor that blocks the RAGE protein's ability to pass on inflammatory signals that injure the heart and kidneys.
https://t.co/i059HdRE0b
Partnership opportunity! @nyulangone's @paganolab has ID'd new small molecule inhibitors of a key enzymatic complex in #coronaviruses to combat #SARSCoV2. The compounds, when combined w/ known drugs, show therapeutic potential as pan-coronavirus antivirals
https://t.co/DPL3wESNvV
Partnership opportunity! @nyulangone researchers have developed new antibodies against cancer target CD99 for the treatment of #leukemia & other blood malignancies -featuring nanomolar target affinity, high target selectivity, low toxicity, & IgG framework
https://t.co/GZmfho29Hq
Despite science’s recent triumphs, the biotech sector is surprisingly having one of its worst market runs in yrs ($XBI -19% YTD) Why? Raising interest rates; waning COVID allure; declining big pharma M&A. See all stats/reasons here👇 #biotech#investing https://t.co/QuIbEsp590
"Structure of a Bacterial ‘Drug Pump’ Reveals New Way to Counter Hospital-Borne Infection"
Thanks @nyulangone for drafting a press release highlighting the importance of our work! @traasethlab@danengw
Check it out: https://t.co/BM9EbwkhSw